Murine models enabled the discovery of immunomodulatory mechanisms for numerous compounds now in clinical development, including demonstration of PSK’s TLR2-mediated immune activation [53,54,98,99] and lentinan’s enhancement of anti-tumor immunity through macrophage activation [100,101,102,103]. This evidence concerns the gene TLR2 and neoplasm.